These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 36795603)

  • 21. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection and quantification of Aβ-3-40 (APP669-711) in cerebrospinal fluid.
    Klafki HW; Wirths O; Mollenhauer B; Liepold T; Rieper P; Esselmann H; Vogelgsang J; Wiltfang J; Jahn O
    J Neurochem; 2022 Mar; 160(5):578-589. PubMed ID: 34984682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.
    Doecke JD; Ward L; Burnham SC; Villemagne VL; Li QX; Collins S; Fowler CJ; Manuilova E; Widmann M; Rainey-Smith SR; Martins RN; Masters CL;
    Alzheimers Res Ther; 2020 Mar; 12(1):36. PubMed ID: 32234072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?
    Sacchi L; Carandini T; Fumagalli GG; Pietroboni AM; Contarino VE; Siggillino S; Arcaro M; Fenoglio C; Zito F; Marotta G; Castellani M; Triulzi F; Galimberti D; Scarpini E; Arighi A
    J Alzheimers Dis; 2022; 85(3):1009-1020. PubMed ID: 34897084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
    Reimand J; Groot C; Teunissen CE; Windhorst AD; Boellaard R; Barkhof F; Nazarenko S; van der Flier WM; van Berckel BNM; Scheltens P; Ossenkoppele R; Bouwman F
    J Alzheimers Dis; 2020; 73(2):559-569. PubMed ID: 31796674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
    Leuzy A; Mattsson-Carlgren N; Cullen NC; Stomrud E; Palmqvist S; La Joie R; Iaccarino L; Zetterberg H; Rabinovici G; Blennow K; Janelidze S; Hansson O
    Alzheimers Dement; 2023 Jul; 19(7):2994-3004. PubMed ID: 36681387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.
    Korecka M; Figurski MJ; Landau SM; Brylska M; Alexander J; Blennow K; Zetterberg H; Jagust WJ; Trojanowski JQ; Shaw LM;
    Clin Chem; 2020 Apr; 66(4):587-597. PubMed ID: 32087019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.
    Schindler SE; Gray JD; Gordon BA; Xiong C; Batrla-Utermann R; Quan M; Wahl S; Benzinger TLS; Holtzman DM; Morris JC; Fagan AM
    Alzheimers Dement; 2018 Nov; 14(11):1460-1469. PubMed ID: 29501462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease.
    Adamczuk K; Schaeverbeke J; Vanderstichele HM; Lilja J; Nelissen N; Van Laere K; Dupont P; Hilven K; Poesen K; Vandenberghe R
    Alzheimers Res Ther; 2015 Dec; 7(1):75. PubMed ID: 26677842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
    Hansson O; Seibyl J; Stomrud E; Zetterberg H; Trojanowski JQ; Bittner T; Lifke V; Corradini V; Eichenlaub U; Batrla R; Buck K; Zink K; Rabe C; Blennow K; Shaw LM; ;
    Alzheimers Dement; 2018 Nov; 14(11):1470-1481. PubMed ID: 29499171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
    Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
    Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
    Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
    BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.
    Salvadó G; Molinuevo JL; Brugulat-Serrat A; Falcon C; Grau-Rivera O; Suárez-Calvet M; Pavia J; Niñerola-Baizán A; Perissinotti A; Lomeña F; Minguillon C; Fauria K; Zetterberg H; Blennow K; Gispert JD;
    Alzheimers Res Ther; 2019 Mar; 11(1):27. PubMed ID: 30902090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.